XBI
Time to buy XBI?$135.99
+$0.31 (0.23%)
2 Days. Real Options Skills.
Join options trader Ben Sturgill as he reveals his most reliable options strategies - live. Seats are limited.
Save your seatTrader's Perspective
XBI ran from roughly $79 in August 2025 to $139.19 in April 2026 off a broad biotech rebound and stronger risk appetite in equal-weighted biotech names.
The stock has the potential to go down if XBI loses $132 and cannot reclaim it fast. That could bring a pullback into the $126 to $130 zone, and any risk-off turn in biotech or disappointing drug approval news would speed up the downside.
If XBI holds the $132 to $135 area, a retest of $139.19 is on the table. A clean push through that level on volume could open a move toward $145, with $139 as the first hurdle.
Analyst Ratings
State Street SPDR S&P Biotech ETF Earnings
We don't currently have information about State Street SPDR S&P Biotech ETF's earnings.